CUREVAC AG

Germany (DE)

OpenCorporation rating: 10.93 on 100

Ranking 2018: 1112 on 2309 companies


Primary and secondary NACE classification:
• Research and experimental development on natural sciences and engineering (7210)
• Scientific research and development (7200)

Company description

This company, based in Germany, operates as a biopharmaceutical firm that engaged in the development of messenger RNA (mRNA) therapeutics. It was established in 2000 and has registered headquarters located in Tuebingen. It is the leading mRNA company with unique expertise and know-how for the production and therapeutic application of mRNA. It offers RNActive, which are mRNA-based cancer immunotherapies and prophylactic vaccines against infectious diseases; RNArt molecular therapies that are designed to trigger the body's own production of therapeutic proteins; and RNAdjuvant RNA encoded antibodies. The company also researches and develops active ingredients for the treatment of cancer, as well as for protection against infectious diseases; and RNActive-based rabies vaccines.

[…] show more

OpenCorporation questionnaire

The read only version of the questionnaire submitted to this company is publicly available: view questionnaire.

score (max is 100)
34.8
14
1.1
0
0
0
0
95

About this evaluation

This company did not compile the OpenCorporation questionnaire, for this reason this evaluation was made only on data available to the project staff.

Claims and support from the company

If as a company manager or official of CUREVAC AG you want to enter in touch with our staff, provide more information to OpenCorporation or get an account to access and compile the company questionnaire, please write an email to support@opencorporation.org .